CHARLOTTE, N.C., March 12, 2010 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the ROTH 21st Annual OC Growth Stock Conference at 11:00 AM PT on March 17, 2010 at The Ritz-Carlton, Laguna Niguel.
Dr. William Schwieterman, Chelsea's Chief Medical Officer, will provide a brief overview of the compa...
CHARLOTTE, N.C., March 10, 2010 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year 2009 and will host a conference call this afternoon at 4:30 PM ET to discuss these results and provide a quarterly update on the Company's development progress.
2009 H...
CHARLOTTE, N.C., March 5, 2010 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it completed its previously announced registered direct offering to institutional investors. The final offering of 6.7 million shares of common stock priced at $2.72 per share along with warrants to purchase approximately 2.3 million shares o...
CHARLOTTE, N.C., March 3, 2010 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release fourth quarter and full year results for the period ended December 31, 2009 after the market closes on Wednesday, March 10, 2010. Chelsea management will host a conference call and live webcast to discuss these financial resul...
CHARLOTTE, N.C., Feb. 26, 2010 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced it has obtained commitments from institutional investors to purchase approximately $18.2 million of its common stock and warrants in a registered direct offering.
At closing, Chelsea will issue 6,700,000 million shares of its common sto...
CHARLOTTE, N.C., Feb. 11, 2010 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, in combination with carbidopa has been initiated in adult attention deficit hyperactivity disorder (ADHD).
ADHD is a neurob...
CHARLOTTE, N.C., Feb. 9, 2010 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced several updates related to its Phase III registration program in neurogenic orthostatic hypotension (NOH), including the selection and preliminary approval by the FDA of Northera™ as the U.S. brand name for Droxidopa in this indication.
...
CHARLOTTE, N.C., Feb. 3, 2010 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 12th Annual BIO CEO & Investor Conference at 1:30 PM ET on Tuesday, February 9th at the Waldorf Astoria Hotel in New York City.
In addition to a brief overview of the company's product pipeline, clinic...
CHARLOTTE, N.C., Dec. 15, 2009 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announces that the FDA has agreed to allow the company to modify the primary endpoint and enroll an additional 24 patients in Study 301, a pivotal Phase III study of Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension (NOH).
...
CHARLOTTE, N.C., Dec. 14, 2009 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that new data from a subgroup analysis of the 44 Parkinson's Disease (PD) patients enrolled in Study 302, a Phase III withdrawal study of Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), demonstrated a more robu...
CHARLOTTE, N.C., Nov. 12, 2009 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that Horacio Kaufmann, M.D. will present results from Droxidopa Study 302 at the American Autonomic Society's 20th Annual International Symposium on the Autonomic Nervous System in St. Thomas, U.S. Virgin Islands. Preliminary results from Study 30...
CHARLOTTE, N.C, Nov. 2, 2009 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced the appointment of William D. Schwieterman, M.D., to the newly created position of Chief Medical Officer. Dr. Schwieterman, who resigned his seat on Chelsea's Board of Directors to assume the position, will be responsible for medical and regulatory ...
CHARLOTTE, N.C., Nov. 2, 2009 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reported financial results for the third quarter 2009. Chelsea's management team will host a conference call this afternoon to discuss these results and present a quarterly update on the Company's development programs at 4:30 PM EST.
Third Qu...
CHARLOTTE, N.C., Oct. 28, 2009 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release third quarter results for the period ended September 30, 2009 after the market closes on Monday, November 2, 2009. Chelsea management will host a conference call and live webcast to discuss these financial results and provide ...
CHARLOTTE, N.C., Oct. 27, 2009 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Oppenheimer 20th Annual Healthcare Conference at 1:00 PM on Wednesday, November 4, 2009 at the Waldorf Astoria Hotel in New York.
Dr. Simon Pedder, President and CEO of Chelsea Therapeutics, will provide a brief ov...
CHARLOTTE, N.C., Oct. 20, 2009 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) will present results from Chelsea's two clinical stage product candidates in its portfolio of metabolically inert antifolate molecules at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting in Philadelphia, Pennsylvania. The presentati...
CHARLOTTE, N.C., Oct. 1, 2009 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that continued analysis of previously reported results from Study 302, the first of two pivotal Phase III trials in Chelsea's registration program of Droxidopa for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH), confirm stat...
CHARLOTTE, N.C., Oct. 1, 2009 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will host a conference call and live webcast to discuss the previously reported results of its Phase III trial of Droxidopa in neurogenic orthostatic hypotension after the market closes at 4:30 PM ET.
Interested investors may pa...
CHARLOTTE, N.C., Sept. 24, 2009 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced top-line results from Study 302, the first of two Phase III trials of Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). While Study 302 demonstrated that Droxidopa showed a strong symptomatic benefit during the ...
CHARLOTTE, N.C., Sept. 15, 2009 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at BioCentury's Newsmakers in the Biotech Industry Conference at 10:30 AM ET on Wednesday, September 16, 2009 at the Millennium Broadway Hotel in New York.
Keith Schmidt, Chelsea's VP of Marketing and Sales, will provide...
Delicious
Digg
Facebook
LinkedIn
Twitter
